A. Ryan

发表

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

J. Wolchok, H. Maecker, A. Shoushtari, 2020, Clinical Cancer Research.

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

J. Wolchok, J. Kirkwood, H. Zarour, 2021, Oncoimmunology.

ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM).

Andrew J. Park, T. Cloughesy, T. Kaley, 2017 .

Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.

Andrew J. Park, T. Cloughesy, T. Kaley, 2017 .

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC).

G. Coukos, P. Sabbatini, P. Schwarzenberger, 2018, Annals of Oncology.

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.

S. Naicker, M. Cahill, J. Krawczyk, 2021, Clinical lymphoma, myeloma & leukemia.

Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.

Andrew J. Park, J. Wolchok, J. Nemunaitis, 2017 .

ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

Andrew J. Park, T. Cloughesy, T. Kaley, 2018, Neuro-Oncology.

Circulating Immune Cell and Outcome Analysis from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.

Raymond Y Huang, Andrew J. Park, T. Creasy, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.

Andrew Roth, Joseph Kaplinsky, M. Middleton, 2023, Cancer cell.

337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab

I. Puzanov, C. Slingluff, P. Friedlander, 2021, Journal for ImmunoTherapy of Cancer.

Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).

Andrew J. Park, T. Cloughesy, T. Kaley, 2019, Journal of Clinical Oncology.

Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT/ASCT) + peripheral blood lymphocyte (PBL) reinfusion.

A. Lesokhin, P. Schwarzenberger, R. Venhaus, 2017 .

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.

S. Naicker, M. Cahill, J. Krawczyk, 2022, Clinical lymphoma, myeloma & leukemia.